- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03863483
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
November 5, 2021 updated by: Xin-Hua Xu
A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of sintilimab or placebo in combination with chemotherapy as second-line treatment for patients with stage IV nonsquamous non-small cell lung cancer with wild-type EGFR after failure with platinum-containing chemotherapy.
Treatment may continue as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Yichang, Hubei, China, 443003
- Recruiting
- Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Volunteer to participate in clinical research; fully understand and know the research and sign informed consent;
- Age ≥ 18 years old and ≤ 75 years old, either sex;
- Eastern Collaborative Oncology Group Performance status (ECOG PS) 0, 1 or 2;
- Has a histologically or cytologically confirmed diagnosis of stage IV (according to the 8th edition of the International Association for the Study of Lung Cancer) nonsquamous NSCLC;
- Have at least one measurable lesion as defined by RECIST 1.1;
- Has progression of disease after treatment with at least two cycles of a platinum-containing doublet chemotherapy according to RECIST V.1.1;
- Patients without activating EGFR mutation;
- Normal hepatic function: total bilirubin≤1.5×normal upper limit (ULN); Alanine aminotransferase and Aspartate aminotransferase levels ≤2.5×ULN or ≤5×ULN if liver metastasis is present;
- Normal renal function: Creatinine ≤1.5×ULN or calculated creatinine clearance ≥45 mL/min (using Cockcroft/Gault formula to calculate );
- Normal hematological function: absolute neutrophil count ≥1.5×109/L, platelet count ≥70×109/L, hemoglobin≥80g/L [no blood transfusion or erythropoietin (EPO) within 7 days] Dependency];
- Has a life expectancy of at ≥3 months.
Exclusion Criteria:
- ECOG PS >2;
- Small cell lung cancer and squamous NSCLC;
- EGFR mutation or mutation status unknown;
- Known hypersensitivity or allergy to monoclonal antibody;
- Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways);
- Active autoimmune disease, or a documented history of autoimmune disease;
- Treatment with systemic corticosteroids (prednisone≥10mg per day or equivalent dose) or other systemic immunosuppressive medications within 2 weeks prior to the first dose;
- Known history or active human immunodeficiency virus (HIV);
- Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection;
- Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment;
- Active or poorly controlled severe infection;
- Have serious cardiovascular disease: Symptomatic congestive heart failure (New York Heart Association grade III-IV), unstable angina pectoris, unstable arrhythmia, myocardial infarction or cerebrovascular accident within 3 months before randomization;
- Received thoracic radiation therapy of >30 Gy within 6 months prior to first dose of study drug;
- Completed palliative radiotherapy within 7 days prior to first dose of study drug;
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sintilimab plus chemotherapy
Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
|
Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
|
ACTIVE_COMPARATOR: Placebo plus chemotherapy
Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
|
Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare Overall Survival (OS) between sintilimab +chemotherapy and placebo + chemotherapy.
Time Frame: approximately 24 months
|
To compare the efficacy of the combination of sintilimab and chemotherapy versus placebo and chemotherapy in terms of overall survival (OS) in patients with stage IV nonsquamous non-small cell lung cancer with wild-type EGFR after failure with platinum-containing chemotherapy.
Overall Survival (OS) was defined as the time from the date of randomization to the date of death due to any cause.
Data for participants who were not reported as dead at the time of analysis was censored at the date when they were last known to be alive.
|
approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants who Experience Treatment Related Adverse Events (AEs).
Time Frame: approximately 24 months
|
All Adverse Events and Serious Adverse events will be collected and collated according to grade and frequency.
AEs graded using CTCAE (Version 4.0) criteria.
|
approximately 24 months
|
Compare objective response rate between sintilimab +chemotherapy and placebo + chemotherapy.
Time Frame: approximately 24 months
|
ORR was defined as the percentage of participants with confirmed objective tumor response, complete response (CR) or partial response (PR), as determined by investigator using RECIST v1.1 criteria.
|
approximately 24 months
|
Compare Progression Free Survival (PFS) between sintilimab +chemotherapy and placebo + chemotherapy using RECIST 1.1.
Time Frame: approximately 24 months
|
PFS was defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first.
Disease progression was determined based on investigator assessment using response evaluation criteria In solid tumors (RECIST) v1.1.
|
approximately 24 months
|
Compare duration of response between sintilimab +chemotherapy and placebo + chemotherapy.
Time Frame: approximately 24 months
|
DOR was defined as the duration from the first tumor assessment that supports the participant's objective response (CR or PR, whichever is first recorded) to disease progression or death due to any cause, whichever occurs first.
|
approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 26, 2019
Primary Completion (ANTICIPATED)
December 31, 2021
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
March 4, 2019
First Submitted That Met QC Criteria
March 4, 2019
First Posted (ACTUAL)
March 5, 2019
Study Record Updates
Last Update Posted (ACTUAL)
November 8, 2021
Last Update Submitted That Met QC Criteria
November 5, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Folic Acid Antagonists
- Docetaxel
- Pemetrexed
Other Study ID Numbers
- CTGU003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonsquamous Non-Small Cell Lung Cancer
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingLung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung CancerPhilippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingLung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung CancerUnited States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
-
Eli Lilly and CompanyCompletedNon-Small Cell Lung Cancer Metastatic | Nonsquamous Non-Small Cell Neoplasm of Lung | Non-Small Cell Lung Cancer Stage IIIBUnited Kingdom, Sweden
-
Incyte CorporationZai Lab (Shanghai) Co., Ltd.Active, not recruitingMetastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung CancerChina, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
-
Taizhou Hanzhong biomedical co. LTDRecruitingNonsquamous Non-small Cell Lung CancerChina
-
Xin-Hua XuRecruiting
-
Xencor, Inc.RecruitingNonsquamous Non-small Cell Lung CancerUnited States
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingNon Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene MutationUnited States, Korea, Republic of, Singapore, Taiwan
-
Beth Israel Medical CenterSt. Luke's-Roosevelt Hospital CenterTerminatedNonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB/IVUnited States
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingNonsquamous Non-small Cell Lung CancerChina
Clinical Trials on Docetaxel
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted
-
SanofiCompletedLung NeoplasmsFrance, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom